Product and Geographic Information (Tables)

9 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

Schedule of Sales of Company's Products

Revenues of the Company’s products were as follows:

	Three Months Ended September 30,												Nine Months Ended September 30,
	2025						2024						2025						2024
($ in millions)	U.S.		Int’l		Total		U.S.		Int’l		Total		U.S.		Int’l		Total		U.S.		Int’l		Total
Women’s Health
Nexplanon/Implanon NXT	$	146	$	77	$	223	$	172	$	70	$	243	$	486	$	225	$	711	$	497	$	207	$	704
Follistim AQ	24		40		64		26		37		63		89		117		206		59		113		171
NuvaRing	9		17		26		7		17		23		21		54		75		33		57		90
Ganirelix Acetate Injection	3		19		22		5		20		26		10		67		77		16		65		82
Marvelon/Mercilon	—		31		31		—		29		29		—		103		103		—		103		103
Jada	20		—		20		15		—		16		53		1		54		42		1		43
Other Women’s Health (1)	17		26		43		14		28		40		47		80		128		41		78		119
General Medicines
Biosimilars
Renflexis	51		19		70		56		16		72		141		49		190		167		43		210
Hadlima	47		16		63		29		11		40		116		44		159		71		27		98
Ontruzant	4		28		31		5		15		20		12		68		80		23		84		107
Brenzys	—		23		23		—		27		27		—		59		59		—		63		63
Other Biosimilars (1)	6		3		9		—		7		7		9		13		22		—		22		22
Cardiovascular
Atozet	—		95		95		—		125		125		—		257		257		—		396		396
Zetia	1		91		93		2		80		81		4		248		252		5		235		240
Cozaar/Hyzaar	2		53		55		2		57		59		6		160		166		7		179		186
Vytorin	1		25		25		1		25		26		3		72		75		4		78		82
Rosuzet	—		6		6		—		11		11		—		16		16		—		36		36
Other Cardiovascular (1)	1		33		33		—		27		29		1		97		98		2		97		99
Respiratory
Singulair	2		51		53		2		83		85		6		187		193		7		268		275
Nasonex	—		60		60		—		63		63		—		197		197		—		200		200
Dulera	24		10		34		38		10		48		89		28		118		120		31		151
Clarinex	1		25		25		1		26		27		1		92		93		2		97		100
Other Respiratory (1)	9		2		12		11		3		14		32		9		40		26		10		35
Non-Opioid Pain, Bone and Dermatology
Arcoxia	—		71		71		—		69		69		—		195		195		—		211		211
Fosamax	—		40		40		1		37		38		2		106		107		3		109		112
Diprospan	—		41		41		—		37		37		—		112		112		—		102		102
Vtama	31		3		34		—		—		—		80		9		89		—		—		—
Other Non-Opioid Pain, Bone and Dermatology (1)	4		75		80		5		69		74		11		217		229		15		212		227
Other
Propecia	2		31		33		2		27		28		4		86		90		5		74		79
Emgality/Rayvow	—		51		51		—		29		29		—		125		125		—		69		69
Proscar	—		27		27		—		23		23		1		73		73		1		72		73
Other (1)	—		86		88		3		80		84		6		245		253		12		229		241
Other (2)	1		21		21		1		26		26		2		66		67		(2)		87		85
Revenues	$	406	$	1,196	$	1,602	$	398	$	1,184	$	1,582	$	1,232	$	3,477	$	4,709	$	1,156	$	3,655	$	4,811

Totals may not foot due to rounding. Trademarks appearing above in italics are trademarks of, or are used under license by, the Organon group of companies.

(1) Includes sales of products not listed separately.

(2) Includes manufacturing sales to third parties.

Schedule of Consolidated Revenues by Geographic Area

Revenues by geographic area where derived are as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
($ in millions)	2025		2024		2025		2024
Europe and Canada	$	417	$	436	$	1,212	$	1,343
United States	406		398		1,232		1,156
Asia Pacific and Japan	251		260		752		806
China	219		212		627		634
Latin America, Middle East, Russia, and Africa	286		243		810		768
Other (1)	23		33		76		104
Revenues	$	1,602	$	1,582	$	4,709	$	4,811

(1) Includes manufacturing sales to third parties.